VIDEO: Awareness of cell therapy, ‘novel therapeutics’ in DLBCL benefits patients, providers

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

It is important for patients, patient advocates, loved ones, as well as general oncologists seeing these patients in the community to be aware that the practice in 2023 is actually very different from what it was even in 2020. And the old pattern of sort of repeated administrations of traditional chemotherapeutics probably needs to be replaced by earlier use of the targeted agents that we talked about including — well, ideally, cell therapy — but if cell therapy is not an option, using some of the novel therapeutics, the antibody-drug conjugates, and now, the bispecifics earlier and in lieu of traditional chemotherapy therapies.